This information was originally presented at the NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ held in Orlando, Florida, from March 23 - 25, 2017.
The 2014 NCCN Case Manager and Medical Director Program consists of five presentations on the topics of biomarkers and targeted therapies, breast cancer, cancer survivorship, clinical trials and drug compendia, and pancreatic cancer.
The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making.
The 2014 NCCN Case Manager and Medical Director Program Live Webinar Series will consist of five webinars on the topics of biomarkers and targeted therapies, breast cancer, cancer survivorship, clinical trials and drug compendia, and pancreatic cancer.
The best treatment strategy for patients with locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC) remains the subject of considerable debate.
Everolimus is an mTOR inhibitor commonly used to treat metastatic pancreatic neuroendocrine tumors (pNETs) and renal cell carcinoma, and for posttransplant immunosuppression.
This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Colorectal, Hepatocellular, Pancreatic, and Gastric/Esophageal Cancers.
This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Colorectal, Hepatocellular, Pancreatic, and Gastric/Esophageal Cancers.
A 59-year-old woman presented with borderline resectable pancreatic adenocarcinoma involving the neck and body of the pancreas. She was treated with systemic chemotherapy followed by chemoradiation, with subsequent downstaging of the tumor by imaging.
Facebook
Twitter
LinkedIn
Forward